Table 4 Overall survival by treatment arm in pre-defined patient subgroups

	N		Univariate cox regression model
	CD	CP	HR	95% CI	Subgroup P -value	Interaction P -value ^a
Age, years
<70	395	423	0.98	0.83, 1.16	0.80	0.61
⩾70	71	86	1.10	0.76, 1.58	0.62
BMI, kg m ^{− 2}
<30	378	399	1.00	0.85, 1.19	0.98	0.74
⩾30	88	110	0.95	0.67, 1.35	0.76
TFI, months
6–12	161	183	1.01	0.80, 1.28	0.92	0.86
⩾12	305	326	0.99	0.81, 1.21	0.90
Measurable disease
No	137	138	0.88	0.65, 1.21	0.56	0.31
Yes	329	371	1.07	0.90, 1.27	0.47
Number of prior lines
1	408	418	0.99	0.84, 1.17	0.92	0.98
⩾2	58	88	0.97	0.65, 1.46	0.74
ECOG PS
0	295	329	0.99	0.81, 1.20	0.92	0.95
⩾1	171	180	0.99	0.78, 1.27	0.95

Abbreviations: BMI=body mass index; CD=carboplatin-pegylated liposomal doxorubicin; CI=confidence interval; CP=carboplatin-paclitaxel; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; TFI=treatment-free interval.
^aInteraction test is the P-value associated with the interaction term in the Cox regression model containing treatment effect, subgroup variable, and their interaction.

Quick links

Search